SUBCLINICAL INFLAMMATION

ANTI INFLAMMATORY EFFECT OF SITAGLIPTIN IN TYPE 2 DIABETIC DYSLIPIDEMIC PATIENTS.

Abstract

Objectives: To evaluate the anti-inflammatory effects of sitagliptin in type 2
diabetic hyperlipidemic patients. Period: 25 August 2015 to 25 November 2015 (12 weeks).
Study Design: Randomized clinical trials. Setting: Outdoor of diabetic clinic of Sheikh Zayed
Medical College/Hospital, Rahim Yar Khan. Materials and Methods: Diabetic patients (n=46)
with poor glycemic control(HbA1c > 7.2%) and deranged lipid profile were selected. The patient
received sitagliptin 50mg twice daily for 12 weeks. Results: A total of 46 patients completed the
study. After 12 weeks treatment with sitagliptin, there was a significant reduction in the value of
HbA1c from 8.26±0.73% at baseline to 7.33±0.62% (p <0.01). Body mass index also decreased
significantly from 31.90±1.57 kg/m2 at baseline to 27.31±1.60 kg/m2 at 12 weeks (p<0.01).
There was also significant reduction in the serum level of total Cholesterol (TC), triglycerides
(TG) and Low density lipoprotein cholesterol( LDL-C) were detected( TC: 255.35±13.89
to 220.76±14.65 mg/dl, TG: 188.80±11.62 to 153.39±9.24 mg/dl,; LDL-C 169.89±12.06 to
147.11±8.1 mg/dl with p-value <0.01. High density lipoprotein cholesterol (HDL-C) increased
significantly from 41.21±3.11 mg/dl at baseline to 50.21±2.37 mg/dl (p <0.01) at 12 weeks.
There is also significant reduction in the value of inflammatory markers after 12 weeks treatment
with sitagliptin, ESR: 27.04±4.07 vs 11.43±1.74 mm/hr, WBC count: 6.90±0.51 vs 5.65±0.34
109/L and hs-CRP: 4.21±0.37 vs 2.16±0.23 mg/L with p-value <0.01. Conclusion: Seeing the
multiple benefits of sitagliptin on risk factors and markers of inflammation it is concluded that it
should be started early in diabetic patients to prevent micro and macro vascular complications
in future.